The company operates an end‑to‑end biopharmaceutical platform that discovers targets, conducts Phase 1‑3 trials, and manufactures biologics, small‑molecule drugs, and vaccines under GMP standards. It aggregates trial and real‑world data in a cloud‑based hub to support regulatory submissions, pharmacovigilance, and outcome analytics, and provides FHIR‑compatible APIs for EHR integration and electronic prescribing. A patient assistance portal offers insurance navigation, co‑pay support, and free medication for eligible patients, improving access for providers and patients treating chronic and acute diseases.
Funding
$1B raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with chronic and acute diseases such as diabetes, cardiovascular disorders, inflammatory conditions, cancers, and infectious threats often face limited therapeutic options, delayed access to innovative treatments, and high out‑of‑pocket costs. The fragmented clinical‑trial landscape and complex supply chains further restrict timely delivery of new medicines and vaccines to the populations that need them most.
Solution
The company operates an integrated biopharmaceutical platform that advances candidates from target discovery through late‑stage clinical development and commercial launch. Leveraging a global network of research sites, it conducts rigorous Phase 1‑3 trials, applies Good Manufacturing Practice (GMP) standards, and utilizes advanced biologics, small‑molecule, and vaccine technologies to generate differentiated therapies. A secure, cloud‑based data hub aggregates trial results and real‑world evidence, supporting regulatory submissions and post‑market surveillance. To improve patient access, the firm offers a structured assistance program that provides insurance navigation, co‑pay support, and free medication for eligible individuals. Clinicians access product information, safety data sheets, and prescribing tools via a web portal that integrates with electronic health‑record (EHR) systems through FHIR‑compatible APIs.
Target Audience
Primary customers are healthcare providers—including physicians, specialists, and pharmacists—who prescribe treatments for chronic diseases, as well as patients eligible for the company’s assistance programs.
Features
- End‑to‑end R&D pipeline covering internal medicine, immunology, oncology, and vaccine development, with over 500,000 preclinical assays and 36+ clinical trials per product.
- GMP‑certified manufacturing facilities and a global supply network ensuring consistent product quality and rapid scale‑up.
- Biologics and biosimilar production platforms, including cell‑culture bioreactors and aseptic fill‑finish lines.
- Integrated clinical‑trial management system that captures electronic case report forms (eCRFs), monitors safety signals, and supports adaptive trial designs.
- Cloud‑based analytics engine that applies machine‑learning models to real‑world data for pharmacovigilance and outcome tracking.
- Secure patient assistance portal (Pfizer RxPathways) offering eligibility screening, co‑pay assistance, and medication delivery logistics.
- API suite compliant with FHIR standards for seamless EHR integration, enabling electronic prescribing and automated adverse‑event reporting.